TAT(SZ:002433)2018-10-24 16:00Financial Performance - Operating revenue for the period reached CNY 778,228,480.44, representing a year-on-year growth of 22.25%[8] - Net profit attributable to shareholders decreased by 6.39% to CNY 85,992,195.63 compared to the same period last year[8] - The company reported a decrease of 24.83% in net profit attributable to shareholders for the year-to-date period, totaling CNY 154,442,053.00[8] - Basic earnings per share decreased by 8.33% to CNY 0.11[8] - The weighted average return on net assets was 1.71%, down by 0.22% from the previous year[8] - The net profit attributable to shareholders for 2018 is expected to range from CNY 290.40 million to CNY 319.44 million, representing a growth of 0.00% to 10.00% compared to the previous year[26] Cash Flow and Investments - Net cash flow from operating activities fell by 35.12% to CNY 26,679,195.98[8] - Net cash flow from operating activities decreased by ¥54,498,777.22, a decline of 71.14% compared to the same period in 2017, mainly due to increased taxes and employee compensation[20] - Cash inflow from financing activities increased by ¥376,604,542.05, a growth of 31.21% compared to the same period in 2017, mainly due to increased bank borrowings[22] - Cash and cash equivalents increased by ¥81,392,506.19, a growth of 53.97% compared to the same period in 2017, primarily due to reduced investments and self-built project expenditures[22] - Investment activities cash outflow decreased by ¥919,060,980.80, a decline of 92.21% compared to the same period in 2017, mainly due to reduced external investments[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,068[12] - The largest shareholder, Taian Group Co., Ltd., holds 32.72% of the shares, amounting to 251,589,701 shares[12] - The company has committed to distributing cash dividends amounting to no less than 30% of the average distributable profit over the next three years, contingent on no major investment plans or significant cash expenditures[25] - The company has committed to prioritizing cash distribution of profits, ensuring at least 10% of the distributable profits are allocated in cash annually[25] Operational Commitments and Compliance - The company has not engaged in any repurchase transactions during the reporting period[13] - The company has no reported violations regarding external guarantees during the reporting period[27] - There are no non-operating fund occupations by controlling shareholders or their affiliates reported during the period[28] - The company has not engaged in any entrusted financial management activities during the reporting period[29] - The company has maintained a commitment to avoid competition and related transactions with listed companies, ensuring compliance until the end of 9999[24] - The company has a lock-up commitment for 4.54 million shares from the initial public offering, which will not be transferred within 36 months from December 28, 2015[24] Expenditures and Liabilities - Accounts receivable decreased by ¥49,650,734.69, a decline of 43.01% compared to the end of 2017, mainly due to endorsement settlement and early discounting[16] - Prepayments increased by ¥83,883,674.19, a growth of 38.90% compared to the end of 2017, primarily due to prepayments for equipment, pharmaceuticals, and medicinal materials[16] - Development expenditures increased by ¥9,816,050.58, a growth of 76.96% compared to the end of 2017, mainly due to increased investment in the E+ operation system V1.0 developed by a subsidiary[16] - Long-term borrowings increased by ¥65,000,000.00, a growth of 50% compared to the end of 2017, due to obtaining a two-year bank loan[16] - Sales expenses increased by ¥88,322,764.46, a growth of 40.00% compared to the same period in 2017, mainly due to increased promotional investments by a subsidiary[17] - Financial expenses increased by ¥27,846,578.84, a growth of 39.17% compared to the same period in 2017, primarily due to increased bank borrowings for operational needs[17] Business Outlook - The company is expected to continue its steady growth in operating performance, reflecting a robust business model[26] - The company has not conducted any research, communication, or interview activities during the reporting period[30]